 Exane Derivatives purchased a new position in Kura Oncology Inc NASDAQ:KURA during the 1st quarter, HoldingsChannel reports. The firm purchased 9,705 shares of the companys stock, valued at approximately 97,000. Several other institutional investors and hedge funds have also recently added to or reduced their stakes in KURA. Marshall Wace LLP bought a new stake ... 